Belumosudil versus ruxolitinib for steroid-refractory or breakthrough hepatic chronic graft-versus-host disease

Phase 4, randomised, open-label trial of belumosudil and ruxolitinib in hepatic chronic graft-versus-host disease (4 cohorts), sponsored by First Affiliated Hospital, Zhejiang University School of Medicine. Primary endpoint: Overall response rate for hepatic chronic graft-versus-host disease at Week 24. Planned start Oct 2026; status: not yet recruiting.